EFFICACY OF AN SIV VACCINE PREPARED WITH DIFFERENT ADJUVANTS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 用由HIV蛋白、gp120和nef/Tat、SIV nef蛋白和各种专有佐剂组成的疫苗免疫动物。经过三次免疫后，动物在1999年接受了SHIV89.6P的静脉攻击。2001年，NIAID将这项实验移交给WaNPRC的SVEU。SVEU的支持将持续到本年度。幸存的动物是长期的非进展者，他们控制病毒复制，保持非常低的或检测不到的病毒水平。应家庭实验室或SVEU项目官员的要求从他们那里收集样本，以监测疫苗和挑战引起的免疫反应的持久性，并根据健康监测需要收集样本。此外，正在采集这些动物的血液，以验证新的细胞内染色分析，这些分析将用于评估为应对正在研究的疫苗以及SVEU合同支持的其他项目而开发的细胞免疫。在本报告期结束前，为了更好地了解疫苗控制病毒的机制，我们计划通过人源化的小鼠抗CD8单抗Cm-T807处理体内的CD8+细胞，检测CD8+细胞在这些动物中控制病毒的作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The animals were immunized with a vaccine composed of HIV proteins, gp120 and nef/tat, and SIV nef protein administered along with various proprietary adjuvants. After three immunizations, the animals were challenged intravenously with SHIV89.6P in 1999. This experiment was transferred to the SVEU at the WaNPRC by NIAID in 2001. SVEU support continues through the current year. The surviving animals are long-term nonprogressors who are controlling virus replication, maintaining very low or undetectable virus levels. Samples are collected from them as requested by the home laboratory or the SVEU project officer to monitor the persistence of immune responses elicited by the vaccine and challenge and as needed for health monitoring. Additionally, blood from these animals is being collected to validate new intracellular staining assays to be used to evaluate cellular immunity developed in response to vaccines being studied on this as well as other projects supported by the SVEU contract. Before the end of this reporting period, in an effort to better understand the mechanisms of virus control by vaccines, we plan to examine the role of CD8+ cells in controlling virus in these animals by temporarily depleting CD8+ cells in vivo by treatment with the humanized mouse monoclonal anti-CD8 antibody, cM-T807.